REG - GSK PLC - GSK receives expanded Shingrix approval in China

GSKAnnouncement

14/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251014:nRSN1853Da&default-theme=true

RNS Number : 1853D  GSK PLC  14 October 2025

Issued: 14 October 2025, London UK

 

GSK's Shingrix approved in China for prevention of shingles in adults aged 18
and over who are at increased risk due to immunodeficiency or
immunosuppression

 

·   Shingrix (GSK's Recombinant Zoster Vaccine or RZV) is the first and
only vaccine approved in this population in China

·   Approval adds to existing indication in adults aged 50 and over

·   Approximately six million cases of shingles occur in China annually, 1 
(#_edn1) with immunodeficient or immunosuppressed patients at a higher risk
than the general population 2  (#_edn2)

 

 

GSK plc (LSE/NYSE: GSK) today announced that the China National Medical
Products Administration (NMPA) has approved Shingrix (GSK's Recombinant Zoster
Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged
18 years and over who are at increased risk of shingles due to
immunodeficiency or immunosuppression caused by known disease or therapy.

 

Shingles poses a significant health burden, with approximately six million
cases per year in China.1 Besides advancing age, other factors can increase
the risk of developing shingles, including immunodeficiency or
immunosuppression 3  (#_edn3) with no other shingles vaccine approved for this
population in China.

 

Shingles-associated pain is often described as aching, burning, stabbing or
shock-like 4  (#_edn4) and can have a considerable impact on patients' quality
of life, e.g.  affecting sleep, and ability to undertake activities of daily
living including work. 5  (#_edn5) (, 6  (#_edn6) , 7  (#_edn7) ) This
approval expands the reach of GSK's RZV, to ensure protection for those
patients most vulnerable to shingles.

 

Sanjay Gurunathan, Senior Vice President, Vaccines and Infectious Diseases
R&D, said: "This approval marks a critical milestone in expanding access
to GSK's RZV for those at a higher risk of what can be a disrupting and
devastating disease. Through close collaboration with regulatory bodies, we
continue to drive innovation that helps protect vulnerable patient groups and
shifting the focus of healthcare systems towards preventing diseases, like
shingles."

 

The NMPA application was informed by six clinical trials in patients aged 18
years and over who had undergone recent blood-forming cells (stem cell)
transplantation, kidney transplant, or have blood cancer, solid tumour, or
HIV. 8  (#_edn8) (, 9  (#_edn9) , 10  (#_edn10) , 11  (#_edn11) , 12 
(#_edn12) , 13  (#_edn13) )

 

About shingles

Shingles is caused by the reactivation of the varicella zoster virus (VZV),
the same virus that causes chickenpox.4 Shingles typically presents as a rash,
with painful blisters across the chest, abdomen or face. 14  (#_edn14)
Following the rash, a person can also experience post-herpetic neuralgia
(PHN), a long-lasting nerve pain that can last weeks or months and can
occasionally persist for several years.4 PHN is the most common complication
of shingles, occurring in 5-30% of all shingles cases. 15  (#_edn15)

 

 

About Shingrix

Shingrix (Recombinant Zoster Vaccine or RZV) is a non-live, recombinant
subunit vaccine indicated for the prevention of shingles in adults 50 and over
and in several countries and regions. RZV is also approved for adults aged 18
years or over at increased risk for shingles. It combines an antigen,
glycoprotein E, with an adjuvant system, AS01(B), and may help overcome the
natural age-related decline in responses to immunisation that contributes to
the challenge of protecting adults aged 50 and over from shingles. RZV is not
indicated to prevent primary varicella infection (chickenpox). The use of RZV
should be in accordance with official recommendations and local product
label.

 

For product and important safety information please consult the country
relevant summary of product characteristics.

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:                 Simon Steel        +44 (0) 20 8047 5502  (London)
                        Simon Moore        +44 (0) 20 8047 5502  (London)
                        Kathleen Quinn     +1 202 603 5003       (Washington DC)
                        Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:    Constantin Fest    +44 (0) 7831 826525   (London)
                        James Dodwell      +44 (0) 20 8047 2406  (London)
                        Mick Readey        +44 (0) 7990 339653   (London)
                        Steph Mountifield  +44 (0) 7796 707505   (London)
                        Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                        Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

References

 

 

 1  (#_ednref1) Zhang, Z., et al. The incidence of herpes zoster in China: A
meta-analysis and evidence quality assessment. Human vaccines &
immunotherapeutics. 2023;19(2):2228169.

 2  (#_ednref2) Zhenwei L, et al. Study on the risk of recurrence of herpes
zoster in adults based on a retrospective cohort design. Zhejiang University
of Traditional Chinese Medicine Conference.

 3  (#_ednref3) Chen, S.Y., et al. Incidence of herpes zoster in patients with
altered immune function. Infection. 2014;42(2):325-34.

 4  (#_ednref4) Harpaz, R., et al. Prevention of herpes zoster:
recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep 2008;57(Rr-5):1-30; .

 5  (#_ednref5) van Oorschot, D.A.M., et al. A Cross-Sectional Concept
Elicitation Study to Understand the Impact of Herpes Zoster on Patients'
Health-Related Quality of Life. Infectious diseases and therapy. 2022;11:501 -
16.

 6  (#_ednref6) Gater, A., et al. The humanistic, economic and societal burden
of herpes zoster in Europe: a critical review. BMC public health. 2015;15:193.

 7  (#_ednref7) Panatto, D., et al. Evaluation of the economic burden of
Herpes Zoster (HZ) infection. Human vaccines & immunotherapeutics.
2015;11(1):245-62.

 8  (#_ednref8) Bastidas, A., et al. Effect of Recombinant Zoster Vaccine on
Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A
Randomized Clinical Trial. JAMA. 2019;322(2):123-33.

 9  (#_ednref9) Vink, P., et al. Immunogenicity and safety of the adjuvanted
recombinant zoster vaccine in patients with solid tumors, vaccinated before or
during chemotherapy: A randomized trial. Cancer. 2019;125(8):1301-12.

 10  (#_ednref10) Dagnew, A.F., et al. Immunogenicity and safety of the
adjuvanted recombinant zoster vaccine in adults with haematological
malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy
analysis. The Lancet Infectious Diseases. 2019;19(9):988-1000.

 11  (#_ednref11) Stadtmauer, E.A., et al. A phase 1/2 study of an adjuvanted
varicella-zoster virus subunit vaccine in autologous hematopoietic cell
transplant recipients. Blood. 2014;124 (19):2921-9.

 12  (#_ednref12) Berkowitz, E.M., et al. Safety and immunogenicity of an
adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a
phase 1/2a randomized, placebo-controlled study. The Journal of infectious
diseases. 2015;211(8):1279-87.

 13  (#_ednref13) GSK. Abstract on file.

 14  (#_ednref14) Mueller, N.H., et al. Varicella zoster virus infection:
clinical features, molecular pathogenesis of disease, and latency. Neurologic
clinics. 2008;26(3):675-97.

 15  (#_ednref15) Kawai, K., et al. Systematic review of incidence and
complications of herpes zoster: towards a global perspective. BMJ open.
2014;4(6).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  READXLFFEBLLFBB



            Copyright 2019 Regulatory News Service, all rights reserved